Executive summary
The way healthcare professionals and patients discover medical information has changed more in the past thirty-six months than in the previous twenty years. Generative artificial intelligence systems — general-purpose assistants such as ChatGPT, Gemini, and Claude; AI-augmented search experiences such as Google AI Overviews; and specialized clinical platforms — no longer point users toward information. They synthesize a single answer and deliver it directly, often without a single click to the underlying source.1,5,6
For most industries this is a marketing challenge. For pharmaceutical companies it is something closer to an existential question of narrative control. When an oncologist asks an AI assistant about the dose modifications of a targeted therapy, or a newly diagnosed patient asks whether a treatment is right for them, the answer they receive is assembled — sentence by sentence — from whatever content the underlying models can find, parse, and trust. If the manufacturer's clinical truth is absent from that synthesis, something else fills the space: third-party aggregators, outdated label versions, community forums, or, in the worst case, statistical hallucination.14,19
Generative Engine Optimization (GEO) is the emerging discipline of structuring digital content so that large language models retrieve it, interpret it correctly, and cite it authoritatively. The term was formalized in a 2024 peer-reviewed study by researchers at Princeton University, Georgia Tech, the Allen Institute for AI, and IIT Delhi, which demonstrated that specific, replicable content interventions can raise a source's visibility in AI-generated answers by up to 40 percent.10 This research synthesizes the published evidence base with GEOMed360's proprietary field research — a multi-model, dual-persona audit programme covering assets across oncology, cardiometabolic disease, and interstitial lung disease — to set out what GEO means for pharmaceutical companies specifically, and what a rigorous GEO operating model looks like across the product lifecycle.
Five findings that should reframe the digital agenda
- 1. The click is no longer the unit of value — the citation is. Google searches that trigger an AI Overview see click-through rates fall from roughly 15 percent to 8 percent, and top-ranked pages lose approximately 58 percent of their clicks; roughly 60 percent of searches now end with no click at all.5,6,8 Health is one of the categories where AI answers appear most frequently.13,21 Traffic-based KPIs systematically understate a brand's real information footprint — and overstate its control of the narrative.
- 2. Adoption has already crossed the tipping point on both sides of the prescription. A March 2026 survey of 1,165 physicians across seven countries found 92 percent using generative AI in clinical practice; a single specialized clinical AI platform now reaches more than 40 percent of practicing US physicians and handles over 20 million clinical queries per month.2,3 On the patient side, more than 40 million Americans ask a general-purpose AI health questions every day, and roughly one in four of its 800 million weekly users sends a health-related prompt each week.1
- 3. Most pharmaceutical content is functionally invisible to the machines now answering the questions. Field audits consistently find that image-based conference posters, slide decks, gated HCP portals, and scanned PDFs generate near-zero AI citations, while third-party aggregators — which the manufacturer does not control — dominate the citation mix.19 In one multi-model audit of a recently launched targeted oncology therapy, manufacturer-owned pages accounted for under 10 percent of citations; gated portal content accounted for none.19
- 4. AI errors about medicines follow predictable, correctable patterns. The most consequential inaccuracies observed in field audits were not random: version confusion between label updates; conflation of pooled and subgroup efficacy data; silence misread as risk; and audience blending between HCP and patient content.19 Each of these maps to a specific, fixable content-structure defect.
- 5. GEO is an operating model, not a campaign. The evidence supports a continuous four-stage cycle — audit, structure, align, monitor — governed jointly by brand, medical, and regulatory functions, prioritized by a content-tier framework, and sequenced against the product lifecycle. Organizations investing more than 5 percent of marketing budgets in AI-search visibility already report materially higher measurable impact than token investors.18